AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteCAY10505 is a potent inhibitor of PI3K, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 μM, respectively).
More Information Supplier PageCAY10505 is a potent inhibitor of PI3K, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 μM, respectively).
More Information Supplier PageCAY10505 is a potent inhibitor of PI3K, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 μM, respectively).
More Information Supplier PageCAY10505 is a potent inhibitor of PI3K, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 μM, respectively).
More Information Supplier PageCB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
More Information Supplier PageCB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
More Information Supplier PageCB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
More Information Supplier PageCB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
More Information Supplier PageCB-839 an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity.
More Information Supplier PageCB-839 an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity.
More Information Supplier PageCB-839 an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity.
More Information Supplier PageCB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .
More Information Supplier PageCB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .
More Information Supplier PageCB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .
More Information Supplier PageCC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 hydrochloride is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 hydrochloride is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-401 hydrochloride is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More Information Supplier PageCC-930 is a selective c-Jun amino-terminal kinase (JNK) inhibitor and is currently under clinical development for fibrotic and infammatory indications.
More Information Supplier PageCC-930 is a selective c-Jun amino-terminal kinase (JNK) inhibitor and is currently under clinical development for fibrotic and infammatory indications.
More Information Supplier PageCC-930 is a selective c-Jun amino-terminal kinase (JNK) inhibitor and is currently under clinical development for fibrotic and infammatory indications.
More Information Supplier PageCCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription.
More Information Supplier PageCCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription.
More Information Supplier PageCCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription.
More Information Supplier PageCCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription.
More Information Supplier PageCCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4.
More Information Supplier PageCCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4.
More Information Supplier PageCCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4.
More Information Supplier PageCCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4.
More Information Supplier PageCCT128930 is an ATP-competitive AKT inhibitor that is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference.
More Information Supplier PageCCT128930 is an ATP-competitive AKT inhibitor that is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference.
More Information Supplier PageCCT128930 is an ATP-competitive AKT inhibitor that is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference.
More Information Supplier PageCCT128930 is an ATP-competitive AKT inhibitor that is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference.
More Information Supplier PageCCT128930 is an ATP-competitive AKT inhibitor that is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference.
More Information Supplier PageCCT129202 is a representative of a structurally novel series of imidazopyridine small-molecule inhibitors of Aurora kinase activity. It shows high selectivity for the Aurora kinases over a panel of other kinases tested and inhibits proliferation in multiple cultured human tumor cell lines.
More Information Supplier Page
